Patricia Sealy
Patricia Sealy
School of Pharmacy, Faculty of Medical Sciences,
Eric Williams Medical Sciences Complex, Bldg 39, Champs Fleurs
Trinidad and Tobago
Biography
Patricia Sealy currently works at the the Centre for Education Programmes, University of Trinidad and Tobago (UTT). Patricia does research in Teacher Education, Social Studies, Youth Development and Environmental studies.
Research Interest
Pharmaceutical Manufacturer's Research Starter Grant: "An Analysis of the Action of Gymnodinium breve
Toxin at the Cell Membrane" Principal Investigator, 1976-1978, $12,000.
NINCDS R01 NS 13727: "Pharmacology of a Mammalian GABA Receptor" Co-Investigator; PI-Joel P.
Gallagher, 1977-1981.
"Electrophysiology and Pharmacology of a Mammalian Dopamine Receptor." American Parkinson's Disease
Foundation; Principal Investigator, 1980-1982, $20,000.
2
NINCDS R01 NS 16228: "Characterization of Mammalian Parasympathetic Ganglia. Principal Investigator,
40% time, 1980-1986, $536,271.
NASA-NAG-2-260: "The identification and pharmacology of neurotransmitters in vestibular nuclei", CoInvestigator,
10% time; PI-Joel P. Gallagher 1983-1992.
USAMRDC DAM-17-86-C-6033: "Direct and Indirect Effects of Cholinesterase Inhibitors at Muscarinic,
Adrenergic and Purinergic Sites in Parasympathetic Ganglia", Principal Investigator, 20% time, 12/1/85 -
11/30/88, $341,079.
HD00768 "Electrophysiology of the SDN-POA and Reproductive Events" Physician/Scientist Award to Mya
Schiess, P.I., P. Shinnick-Gallagher, Sponsor, 10% time, 1986-1989.
NINDS-NS-16228-09: "Characterization of Mammalian Parasympathetic Ganglia". P. Shinnick-Gallagher,
Principal Investigator, 25% time, 4/1/87 - 3/31/90, $294,179.
NINDS R01 NS 24643: "Epileptogenesis in the Amygdala: Physiology, Pharmacology". P. Shinnick-Gallagher,
Principal Investigator, 25% time, 2/1/88 - 1/31/92, $324,708.
NINDS R01 NS 29265: "CRF in the amygdala" P. Shinnick-Gallagher, Principal Investigator, 25% time, 2/1/91 -
1/31/97, 01 - $379,840.
NINDS R01 NS 24643: "Epileptogenesis in the Amygdala" P. Shinnick-Gallagher, Principal Investigator, 25%
time, 12/01/92 - 11/30/97, $390,109.
NOVA Pharmaceutical Corp. "Development of a Novel Corticotropin - Releasing Factor Antagonist", P.
Shinnick-Gallagher, Principal Investigator. 08/01/91 – 4/30/97; $5,000.
John Sealy Memorial Endowment Fund “Amygdala and Fear Conditioning”: P. Shinnick-Gallagher, Principal
Investigator. 09/01/95 - 08/31/98, $100,000.
F30 MH11221-03 Research Fellowship Award: Amygdala and Fear Conditioning, Margaret McKernan;
Sponsor: P. Shinnick-Gallagher, 11/1/95 - 10/31/99, $12,633/yr.
Pharmaceutical Research and Manufacturers of America Foundation, Medical Student Research Fellowship in
Pharmacology - Clinical Pharmacology, Margaret McKernan; Sponsor: P. Shinnick Gallagher, 7/1/95 - 2/1/97,
$10,000.
NIDA T32-DA072287 “Neuronal and Pharmacological Mechanisms of Abused Drugs” Pre- and Postdoctoral
Training Grant, Kathryn Cunningham, PI, P. Shinnick-Gallagher, Advisor.
NINDS R01 NS24643-08-13: “Epileptogenesis in the Amygdala” P. Shinnick-Gallagher, Principal Investigator,
25% time, 07/01/97 - 03/31/02, $673,184 direct costs.
NIMH RO1-MH58327: “Amygdala Neurons and Fear Conditioning”. P. Shinnick-Gallagher, Principal
Investigator, (25% time), 8/01/98-7/31/03, $671,893.
NIDA R01 DA11991-03 “CRF Mechanisms and Cocaine” Joel P. Gallagher, Principal Investigator, P. ShinnickGallagher,
Co-PI (15% time), 05/1/99- 3/31/04, $914,172 direct costs.
Pilot Research Grants in the Neurosciences (PRN Grant # 4009-02) UTMB: Heritable anxiety traits and
propensity for drug dependence: basic and clinical science measures” P. Shinnick-Gallagher, PI (10%) time,
2/1/02-8/31/04, $50,000.
3
NIMH MH067458 Predoctoral Fellowship: Bradley W. Schroeder: “Amygdala Synaptic Plasticity in Fear
Learning”, 07/01/03-6/30/07.
John Sealy Memorial Endowment Fund “Amygdala and Fear Conditioning”, Bridging grant. P. ShinnickGallagher
Principal Investigator, 06/01/04 - 05/31/05, $35,000.
NIDA RO1 DA177270-01 Amygdala neurons and cocaine, P. Shinnick-Gallagher, PI (40% time), 07/01/2005-
6/30/2010 direct costs, $200,000/yr.
